GANX
Gain Therapeutics Inc

2,612
Mkt Cap
$75M
Volume
760,671.00
52W High
$4.34
52W Low
$1.41
PE Ratio
-3.05
GANX Fundamentals
Price
$1.95
Prev Close
$1.90
Open
$1.90
50D MA
$2.17
Beta
1.22
Avg. Volume
682,387.46
EPS (Annual)
-$0.892
P/B
11.87
Rev/Employee
$0.00
$39.69
Loading...
Loading...
News
all
press releases
Gain Therapeutics (GANX) Expected to Announce Earnings on Thursday
Gain Therapeutics (NASDAQ:GANX) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 26. (View Earnings Report at...
MarketBeat·4d ago
News Placeholder
More News
News Placeholder
Gain Therapeutics (NASDAQ:GANX) Trading Up 3.7% - What's Next?
Gain Therapeutics (NASDAQ:GANX) Stock Price Up 3.7% - Should You Buy...
MarketBeat·6d ago
News Placeholder
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the seven analysts that are presently covering the firm, Marketbeat reports. One...
MarketBeat·30d ago
News Placeholder
Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Up 19.9% in January
Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) was the recipient of a significant increase in short interest during the month of January. As of January 30th, there was short interest...
MarketBeat·1mo ago
News Placeholder
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Shares of Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the seven brokerages that are currently covering the stock...
MarketBeat·2mo ago
News Placeholder
Short Interest in Gain Therapeutics, Inc. (NASDAQ:GANX) Rises By 28.6%
Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) was the target of a significant growth in short interest during the month of December. As of December 31st, there was short interest totaling...
MarketBeat·2mo ago
News Placeholder
Gain Therapeutics Shares Early Phase 1b Data: GT-02287 Shows UPDRS Gains, Key PD Biomarker Drop
Gain Therapeutics (NASDAQ:GANX) highlighted early clinical and biomarker findings from the first 90 days of its ongoing Phase 1b open-label study evaluating GT-02287 in people with Parkinson's...
MarketBeat·3mo ago
News Placeholder
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Rating of "Moderate Buy" from Brokerages
Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the seven brokerages that are currently covering the firm, Marketbeat reports. One...
MarketBeat·3mo ago
News Placeholder
Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Update
Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) saw a significant growth in short interest in December. As of December 15th, there was short interest totaling 2,073,310 shares, a growth of...
MarketBeat·3mo ago
News Placeholder
Gain Therapeutics (GANX) Upgraded to Buy: Here's Why
Gain Therapeutics (GANX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·3mo ago
<
1
2
...
>

Latest GANX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.